Interim Management Statement

RNS Number : 6600H

Dechra Pharmaceuticals PLC

07 November 2008

 



Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Friday, 7 November 2008

Dechra® Pharmaceuticals PLC

Interim Management Statement

Dechra Pharmaceuticals PLC ('Dechra' or the 'Group'), which holds its Annual General Meeting today at 9.00am, publishes its Interim Management Statement covering the period from 1 July 2008 to the date of this announcement as required by the UK Listing Authority Disclosure and Transparency Rules.

The Group has started the financial year in line with management expectations. There have been no material events or transactions during the relevant period and the financial position of the Group remains strong.

The Pharmaceuticals Division has continued its strong growth with revenue for the first quarter of the financial year ahead of the same period last year. We are making good progress in the USA as we recruit sales and technical support personnel ahead of the January 2009 launch of Vetoryl®.  VetXX® (now rebranded Dechra Veterinary Products EU) continues to make sound progress.

The Services Division continues to take advantage of resilient market conditions, with market share at National Veterinary Services® remaining above 44%.

The Board remains confident that the Group will continue to make good strategic progress in line with management expectations throughout the remainder of the financial year.

Enquiries:
Ian Page, Chief Executive
Simon Evans, Group Finance Director	Fiona Tooley, Director
Dechra Pharmaceuticals PLC	Citigate Dewe Rogerson
Tel: [phone]	Tel: [phone]
Mobile: [phone] (IP) or 07775 642220 (SE)	Mobile: [phone]
www.dechra.com
[e-mail]

Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

IMSILFSRLILRIIT